Heptyl D-glucoside | 100231-64-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Heptyl D-glucoside
• 英文别名: 2-heptoxy-6-(hydroxymethyl)oxane-3,4,5-triol
• CAS: 100231-64-9
• 化学式: C₁₃H₂₆O₆
• 分子量: 278.34
• InChiKey: NIDYWHLDTIVRJT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  19
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  99.4
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS
  申请人：Janetka James W.

  公开号：US20120309701A1

  公开（公告）日：2012-12-06

  The present invention encompasses compounds and methods for treating urinary tract infections.

  本发明涵盖了治疗尿路感染的化合物和方法。
• OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
  申请人：WAVE LIFE SCIENCES LTD.

  公开号：US20200190515A1

  公开（公告）日：2020-06-18

  Among other things, the present disclosure provides designed PNPLA3 oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide improved single-stranded RNA interference and/or RNase H-mediated knockdown. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., RNA interference (RNAi) activity, stability, delivery, etc. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions, for example, in RNA interference and/or RNase H-mediated knockdown.
• OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF
  申请人：WAVE LIFE SCIENCES LTD.

  公开号：US20210228615A1

  公开（公告）日：2021-07-29

  Among other things, the present disclosure provides technologies for altering splicing, particularly for increasing inclusion of exons in splicing products. In some embodiments, the present disclosure provides SMN2 oligonucleotides, compositions, and methods thereof. In some embodiments, the present disclosure provides chirally controlled SMN2 oligonucleotide compositions. In some embodiments, provided oligonucleotides and compositions can increase level of an exon 7-containing SMN2 splicing product and/or a gene product thereof. In some embodiments, the present disclosure provides methods for treatment of splicing-related conditions, disorders and diseases. In some embodiments, the present disclosure provides methods for treating SMN2-related conditions, disorders and diseases such as SMA (spinal muscular atrophy) and ALS (amyotrophic lateral sclerosis).
• US8937167B2
  申请人：——

  公开号：US8937167B2

  公开（公告）日：2015-01-20
• US9750813B2
  申请人：——

  公开号：US9750813B2

  公开（公告）日：2017-09-05